Key opinion leaders share their thoughts on the prospect of effector cell redirection and cell engagers at Biologics UK: In-Person 2022.

Researchers from ETH Zurich demonstrate the promise of deep learning for predicting antigen specificity.

Glyn Stacey, Chief Executive at SSCBio leads a discussion on the current landscape of ‘Cell Therapy Analytics'.

Amir Reza Goudarzi, former Engineering Head of UCB in Brussels, leads a discussion on ‘Upstream Bioprocessing.'

Key opinion leaders from Novartis, Achilles Therapeutics, and AbbVie divulge their views on what's next for upstream bioprocessing.

Bringing together the experts to discuss the timeline of autoimmune disease therapeutics.

What’s next for CAR T cell therapy? What’s the best way to develop combination therapies for multi-modal efficacy?

This Commentary article investigates the potential applications of digital twins in refining the developmental timeline for drug substance development. Capturing and conserving the understanding from ongoing processes allows researchers to learn more about the intricacies of the developmental process more rapidly.

In this Commentary article, we explore how innovative technologies like expression tags could help to overcome challenges associated with recombinant peptide production. The potential for recombinant production to slash manufacturing costs has made it a focal area of research for companies such as Boehringer Ingelheim.

UCB, Bicycle Therapeutics, and Sanofi share their latest findings in Peptide discovery at Biologics UK 2022.

Oxford Global’s Discussion Groups provide a focused networking opportunity for a handful of like-minded experts on a monthly basis. Our April Discussion Group addressing ‘Accelerating Antibody Engineering With AI/ML & Advanced Computational Tools and Technologies’ brought together an exclusive panel of key opinion leaders to address the market’s growth and future outlook.

Video Interview | Namir Hassan, CEO at Zelluna Immunotherapy